Relative Bioavailability of 2 Fixed Dose Combinations of Empagliflozin/Linagliptin/Metformin Extended Release Compared With Single Tablets

NCT02821910 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

50

Enrollment

INDUSTRY

Sponsor class

Conditions

Healthy

Interventions

DRUG: High dose FDC Empagliflozin/Linagliptin/Metformin XR, fed
DRUG: 1 tab Empagliflozin +1 tab Linagliptin +2 tabs Metformin XR
DRUG: High dose FDC Empagliflozin/Linagliptin/Metformin XR, fasted
DRUG: 1 tab Empagliflozin +1 tab Linagliptin +2 tabs Metformin XR
DRUG: Low dose FDC Empagliflozin/Linagliptin/Metformin XR, fed
DRUG: 1 tab Empagliflozin +1 tab Linagliptin +2 tabs Metformin XR

Sponsor

Boehringer Ingelheim

Collaborators

[object Object]